KR870009023A - IL-1α 유도체의 제조방법 - Google Patents

IL-1α 유도체의 제조방법 Download PDF

Info

Publication number
KR870009023A
KR870009023A KR870002331A KR870002331A KR870009023A KR 870009023 A KR870009023 A KR 870009023A KR 870002331 A KR870002331 A KR 870002331A KR 870002331 A KR870002331 A KR 870002331A KR 870009023 A KR870009023 A KR 870009023A
Authority
KR
South Korea
Prior art keywords
formula
amino acid
derivative
asn
substituted
Prior art date
Application number
KR870002331A
Other languages
English (en)
Other versions
KR950000886B1 (ko
Inventor
사또루 나가이
마유미 가네다
요시까즈 기꾸모도
홍영만
가즈요시 가와이
세스꼬 다께가따
기요시 이시이
야스오 야나기하라
요시가쓰 히라이
Original Assignee
오오스까 아끼히꼬
오오쓰까 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오오스까 아끼히꼬, 오오쓰까 세이야꾸 가부시끼가이샤 filed Critical 오오스까 아끼히꼬
Publication of KR870009023A publication Critical patent/KR870009023A/ko
Application granted granted Critical
Publication of KR950000886B1 publication Critical patent/KR950000886B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L5/00—Devices for use where pipes, cables or protective tubing pass through walls or partitions
    • F16L5/02—Sealing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mechanical Engineering (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

IL―1α유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 플라스미드 pcD-GIF-16 및 플라스미드 pcD-GIF-207의 cDNA의 제한효소지도를 나타내고
제 2도는 플라스미드pcD-GIF-207 및 플라스미드 pTM1으로부터 플라스미드 ptrpIL-1α-113이 구성되는 방법을 나타내는 도면이고;
제 3도는 항암활성 시험결과를 나타내고 ;

Claims (7)

  1. IL―1α 유도체의 유전정보를 지정하는 유전자를 포함하는 발현 운반체를 갖는 재조합 미생물을 배양하여 상기 유도체를 생산하고 생산된 유도체를 수집함을 포함하는 IL―1α 유도체의 제조방법으로, 상기 IL―1α 유도체가 식(A)에서 36위치의 Asn 및 141 위치의 Cys중의 최소한 하나가 결핍되거나 다른 아미노산으로 치환된 식으로 표시되는 IL―1α의 아미노산 서열을 갖는 폴리펩티드임을 특징으로 하는 방법.
    식(A) :
  2. 제 1항에 있어서, 상기 폴리펩티드가 식(A)에서 최소한 36 위치의 Asn이 결핍되거나 다른 아미노산으로 치환된 아미노산 서열을 갖는 것임을 특징으로 하는 IL―1α 유도체의 제조방법.
  3. 제 1항에 있어서, 상기 폴리펩티드가 식(A)에서 36 위치의 Asn이 Asp으로 치환된 아미노산 서열을 갖는 것임을 특징으로 하는 IL―1α 유도체의 제조방법.
  4. 제 1항에 있어서, 상기 폴리펩티드가 식(A)에서 36위치의 Asn 및 141 위치의 Cys가 각각 Asp 및 Ser으로 치환된 아미노산 서열을 갖는 것임을 특징으로 하는 IL―1α 유도체의 제조방법.
  5. 식(A)에서 36 위치의 Asn 및 141 위치의 Cys 중의 최소한 하나가 결핍되거나 다른 아미노산으로 치환된 식으로 표시되는 IL―1α 유도체의 유전정보를 지정하는 유전자의 제조방법으로, IL―1α의 유전정보를 지정하는 유전자의 헥산서열을 변형시켜 상기 폴리펩티드의 변형된 아미노산 서열의 유전정보를 지정하는 유전자를 수득함을 특징으로 하는 방법.
    식(A) :
  6. 식(A)에서 36 위치의 Asn 및 141 위치의 Cys 중의 최소한 하나가 결핍되거나 다른 아미노산으로 치환된 식으로 표시되는 IL―1α의 발현 운반체의 제조방법으로, 제 5항의 방법으로 수득한 유전자를 운반체에서 상기 유전자의 발현을 허용하는 부위에 삽입함을 특징으로 하는 방법.
  7. 제조한 미생물의 제조방법으로, 제 6항의 방법으로 수득한 발현 운반체를 숙주세포에 도입함을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870002331A 1986-03-14 1987-03-14 IL-Iα 유도체의 제조방법 KR950000886B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP57885 1986-03-14
JP5788586 1986-03-14
JP12975986 1986-06-03
JP129759 1986-06-03
JP14839386 1986-06-25
JP160250 1986-07-08
JP16025086 1986-07-08
JP200323 1986-08-27
JP20032386 1986-08-27
JP148393 1989-06-13

Publications (2)

Publication Number Publication Date
KR870009023A true KR870009023A (ko) 1987-10-22
KR950000886B1 KR950000886B1 (ko) 1995-02-03

Family

ID=27523408

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870002331A KR950000886B1 (ko) 1986-03-14 1987-03-14 IL-Iα 유도체의 제조방법

Country Status (8)

Country Link
US (5) US5008374A (ko)
EP (2) EP0237073B1 (ko)
JP (1) JP2572220B2 (ko)
KR (1) KR950000886B1 (ko)
DE (1) DE3750432T2 (ko)
DK (2) DK171647B1 (ko)
ES (1) ES2009216A6 (ko)
HK (1) HK1003115A1 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
JP2698976B2 (ja) * 1988-02-03 1998-01-19 大日本製薬株式会社 新規ポリペプチド及びそれをコードするｄｎａ
US5290917A (en) * 1988-02-03 1994-03-01 Dainippon Pharmaceutical Co., Ltd. Modified polypeptides of IL-1α
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
EP0644203A1 (en) * 1988-07-29 1995-03-22 Otsuka Pharmaceutical Co., Ltd. IL-1alpha derivatives and medicament for treating thrombocytopenia
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
AU5171890A (en) * 1989-02-27 1990-09-26 Massachusetts Institute Of Technology Il-1 biological activity inhibitors
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
DE69126116T2 (de) * 1990-08-10 1997-08-28 Otsuka Pharma Co Ltd Wirkstoff zur hepatitisverhütung und -behandlung
US5723117A (en) * 1990-08-10 1998-03-03 Otsuka Pharmaceutical Co., Ltd. Use of interleukin-1 (IL-1) to inhibit development of hepatitis
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤
JPH06196070A (ja) * 1992-12-24 1994-07-15 Nec Corp 電磁継電器
US5866134A (en) * 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
US7176179B1 (en) 1997-05-30 2007-02-13 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
US6191269B1 (en) 1997-05-30 2001-02-20 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
WO1999037321A1 (fr) * 1998-01-22 1999-07-29 Gosudarstvenny Nauchno-Issledovatelsky Institut Osobo Chistykh Biopreparatov (Gosnii Ochb) Preparation immuno-modulatrice a base d'interleukine 1 et procede de preparation
US20030154504A1 (en) * 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
WO2002061111A2 (en) * 2000-12-15 2002-08-08 Stratagene Room temperature stable competent cells
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US20030211624A1 (en) * 2001-11-20 2003-11-13 Board Of Regents, The University Of Texas System Proteomic methods for diagnosis and monitoring of breast cancer
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568640A (en) * 1981-05-11 1986-02-04 Harvey Rubin Method of inserting amino acid analogs into proteins
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4512974A (en) * 1982-12-08 1985-04-23 Moldawer Lyle L Treatment of protein malnourished surgical patients
US4542017A (en) * 1982-12-09 1985-09-17 Moldawer Lyle L Treatment of protein malnourished bacterially infected humans with LEM
FR2550802B1 (fr) * 1983-08-17 1986-04-11 Inst Nat Sante Rech Med Procede de production d'interleukine 1 humaine et medicaments correspondants
JPS60149386A (ja) * 1984-01-17 1985-08-06 Dainippon Pharmaceut Co Ltd インタ−ロイキン１をコ−ドする伝令リボ核酸及びその調製法
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
EP0155433A1 (en) * 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
DE3588241T2 (de) * 1984-05-18 2002-12-05 Massachusetts Institute Of Technology, Cambridge Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
CA1341433C (en) * 1984-06-19 2003-06-24 Douglas P. Cerretti Purification of interleukin 1
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
DE3587605T2 (de) * 1984-12-25 1994-03-17 Dainippon Pharmaceutical Co Interleukin-1 und dessen Derivat.
AU577856B2 (en) * 1985-01-17 1988-10-06 Immunex Corporation Cloning and characterization of the human interleukin 1 gene
DE3683186D1 (de) * 1985-04-25 1992-02-13 Hoffmann La Roche Rekombinantes humaninterleukin-1.
IT1188550B (it) * 1986-02-07 1988-01-14 Sclavo Spa Peptide sintetico ad attivita' interleukina 1 umana
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US5017692A (en) * 1986-09-04 1991-05-21 Schering Corporation Truncated human interleukin-a alpha
US5047505A (en) * 1987-01-27 1991-09-10 Du Pont Merck Pharmaceutical Company High level expression in E. coli of soluble mature HIL-1beta and derivatives with altered biological activity
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5211946A (en) * 1991-09-13 1993-05-18 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides

Also Published As

Publication number Publication date
DK172339B1 (da) 1998-04-06
DE3750432T2 (de) 1995-04-20
JPS63164899A (ja) 1988-07-08
EP0578278A1 (en) 1994-01-12
US5543140A (en) 1996-08-06
DK127787D0 (da) 1987-03-12
HK1003115A1 (en) 1998-10-09
DK51493D0 (da) 1993-05-05
US5342615A (en) 1994-08-30
EP0237073B1 (en) 1994-08-31
DE3750432D1 (de) 1994-10-06
US5008374A (en) 1991-04-16
US5371204A (en) 1994-12-06
KR950000886B1 (ko) 1995-02-03
ES2009216A6 (es) 1989-09-16
DK51493A (da) 1993-05-05
DK171647B1 (da) 1997-03-03
EP0237073A3 (en) 1989-11-15
JP2572220B2 (ja) 1997-01-16
US5702698A (en) 1997-12-30
DK127787A (da) 1987-09-15
EP0237073A2 (en) 1987-09-16

Similar Documents

Publication Publication Date Title
KR870009023A (ko) IL-1α 유도체의 제조방법
KR920012442A (ko) 피치아 파스토리스 산성 인산효소 유전자의 dna 단편 및 이를 사용하는 방법
ATE111156T1 (de) Transientes expressionssystem zur herstellung von rekombinantem protein.
KR870000427A (ko) 하이브리드 인터페론의 제조방법
KR930006153A (ko) 인간응집인자 viii 단백질 복합체의 제조방법
RU98107565A (ru) Получение рекомбинантного фактора viii в среде, не содержащей белка
KR870002264A (ko) 폴리-크링글 플라스미노겐 활성화제의 제조방법
ATE78055T1 (de) Verfahren zur herstellung von proteinen und transformierten zellen und dna-konstruktionen zur korrektur von mankos und wirtszellen sowie deren herstellung und verwendung.
ATE140009T1 (de) Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
ATE194651T1 (de) Stammzellenfaktor
KR920702417A (ko) Tcf-ii의 아미노산 배열을 코드하는 dna를 함유한 플라스미드, 형질전환세포, 및 이것을 사용하여 생리 활성물질을 생산하는 방법
ATE152124T1 (de) Wachstumsfaktor aus parenchymalen lebenszellen, dafür kodierendes gen, verfahren zur herstellung dieses faktors und transformanten
KR900014428A (ko) 신규폴리펩타이드 및 그 제조방법
DE69430975T2 (de) Verfahren zur Herstellung von Proteinen
KR870002162A (ko) α-hANP-(17-28)의 제조방법
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
ATE66251T1 (de) Expressionsplasmide fuer die herstellung eines heterologen proteins in bakterien.
KR880000587A (ko) 리소자임의 제조방법
DE69431068D1 (de) Das polypeptid eines membran-proteins mit der funktion zur unterstützung des wachstums von prä-b zellen und sein gen
Burnside et al. Tubulin determination by an isotope dilution-vinblastine precipitation method: the tubulin content of Spisula eggs and embryos
JPS6490199A (en) T cell growth factor derived from thymic interstitial cell and production thereof
KR950018454A (ko) 단백질 c를 생성시키는 방법
DK600386D0 (da) Proteinekspression
DE69017793D1 (de) Produktion von menschlichen Nervenwachstumsfaktoren.
Okamoto et al. Amplification and high-level expression of a cDNA for human granulocyte-macrophage colony-stimulating factor in human lymphoblastoid Namalwa cells

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990123

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee